29 / 56
29
Scientific programme
Friday, 21 April 2017
P-16-005 A personalized medicine approach to
ADHD: Patient factors in selecting ADHD
pharmacological agents
N. Amaladoss, Canada
P-16-006 Factors related to dropout frommethyl
phenidate of adolescents with ADHD
D. Guizar-Sánchez, Mexico
F. De la Peña-Olvera, L. Palacios-Cruz
P-16-008 ADHD and comorbidities in the Indian re-
gion – how essential is pharmcotherapy?
A. Vaithiyam, India
K. Devandran
P-16-009 Is video-assisted methylphenidate dose
finding for children with ADHD a suit-
able procedure for medical practition-
ers? Results after 4-year follow-up
H.-J. Kuehle, Germany
T. Glaser, G. Neuhäuser
P-16-010 Efficacy and safety of HLD200, a
novel delayed-release and extended-
release methylphenidate formulation,
in children with Attention-Deficit/
Hyperactivity Disorder: Results from a
pivotal phase 3 trial
S. Pliszka, USA
V. Arnold, A. Marraffino, N. DeSousa, B.
Incledon, F. Sallee, T. Wilens, J. Newcorn
P-16-011 Dose proportionality and effect of food
on the pharmacokinetics of HLD200, a
novel delayed-release and extended-
release methylphenidate formulation
in healthy adults
F. Sallee, Cayman Islands
T. Liu, J. Gobburu, A. McLean, B. Incledon
P16-012 Dasotraline efficacy throughout the
day in children with attention deficit
hyperactivity disorder: Results of a phase
3, randomized, double-blind, placebo-
controlled study in a laboratory class-
room setting
Sharon Wigal, USA
R. Goldman, A. Childress, S. C. Hopkins,
K. S. Koblan, K. Sarma, X. Wan, A. Loebe
P-17
Guided Poster Tour
14:30–16:00
Exhibit Hall A
Pharmacological treatment children and ado-
lescents II
Chair:
D. Coghill, Australia
P-17-001 Double-blind, placebo-controlled study
of the novel therapeutic AEVI-001 in ad-
olescents with ADHD and glutamatergic
network gene mutations
L. Squires, USA
D. Fitts
P-17-003 The comparison of methylphenidate and
atomoxetine on cognitive functions in
children and adolescents with ADHD:
A meta-analysis
J. Ren, People‘s Republic of China
Y. Li, S. Yue, J. Yue, Q. Li, M. Lv, L. Tie
P-17-004 Cognitive function in children and ado-
lescents with ADHD receiving lisdexam-
fetamine dimesylate in a 2-year safety
study
D. Coghill, Australia
T. Banaschewski, 2, C. Bliss, B. Robertson,
A. Zuddas
P-17-005 Growth and sexual maturation in a
two-year, open-label clinical study of
lisdexamfetamine dimesylate in children
and adolescents with ADHD
D. Coghill, Australia
I. Hernández Otero, M. Johnson, P. Nagy,
C. A. Soutullo, A. Zuddas, B. Yan, T.
Banaschewski
P-17-006 Weight and height in children and
adolescents with Attention-Deficit/
Hyperactivity Disorder: A longitudinal
database study assessing the impact of
guanfacine, stimulants or no pharma-
cotherapy
W. Spalding, USA
T. Banaschewski, B. Feldman, P. Gustafsson,
B. Murphy, M. Reynolds, D. Coghill, G.
Schneider